Experts advocate for using AKT inhibitors in the early, hormone-sensitive setting for PTEN-deficient prostate cancer. The rationale is that early-stage disease is more dependent on the AKT pathway. In later, castrate-resistant stages, the cancer develops other resistance mechanisms and alterations, diminishing the potential impact of a targeted AKT inhibitor.

The CAPItello-281 trial shows the benefit of the AKT inhibitor capivasertib is on a spectrum. Patients with 100% PTEN protein loss by IHC derive a much greater benefit than those with partial loss, suggesting a quantitative biomarker may optimize patient selection.

In castration-resistant states, prostate cancer cells often amplify their androgen receptors (AR) to survive low testosterone levels. Bipolar androgen therapy exploits this by introducing a massive surge of testosterone. This "shocks" the over-amplified AR system, causing it to regress and disrupting downstream tumor growth pathways.

The AKT pathway, activated by PTEN loss, drives cancer growth independently of the androgen receptor, which controls PSA production. This discordance means clinicians cannot rely on PSA alone and must use systematic imaging to detect progression in this specific patient subgroup.

PTEN loss is seen very early in prostate cancer development. However, its primary role is not initiating the cancer but rather accelerating its progression in grade, stage, and disease state. The initial driver is more often related to androgen receptor biology.

The panel suggests AKT inhibitor trials in prostate cancer have been disappointing due to suboptimal biomarker selection (e.g., PTEN IHC). A similar drug in breast cancer showed significant survival benefit when using a more precise NGS-based strategy, indicating a potential path forward if the right patient population is identified genetically.

In patients with PTEN loss, cancer growth is driven by the PI3K-AKT pathway, which doesn't activate the PSA gene. This can lead to significant disease progression with a low or stable PSA, making PSA a poor surrogate for disease activity in this sub-population.

Loss of the P10 tumor suppressor gene leads to a more aggressive prostate cancer phenotype by activating the PI3K/AKT survival pathway. This genetic alteration also serves as a predictive biomarker for treatment with AKT inhibitors like capivacertib.

The CAPItello-281 trial showed that the clinical benefit of adding the AKT inhibitor capivasertib is directly proportional to the degree of PTEN loss. The greatest separation in survival curves was seen in patients with 99-100% PTEN loss by IHC, suggesting the current trial entry cutoff of >90% may be too broad for optimal patient selection.